These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
200 related articles for article (PubMed ID: 27798667)
1. Body Mass Index with Tumor 18F-FDG Uptake Improves Risk Stratification in Patients with Breast Cancer. Hyun SH; Ahn HK; Lee JH; Choi JY; Kim BT; Park YH; Im YH; Lee JE; Nam SJ; Lee KH PLoS One; 2016; 11(10):e0165814. PubMed ID: 27798667 [TBL] [Abstract][Full Text] [Related]
2. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer. Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369 [TBL] [Abstract][Full Text] [Related]
3. Influence of Body Mass Index on the Prognostic Value of Tumor ¹⁸F-FDG Uptake in Stage I Non-Small Cell Lung Cancer. Hyun SH; Lee KH; Choi JY; Kim BT; Kim J; Zo JI; Kim H; Kwon OJ; Ahn HK PLoS One; 2015; 10(12):e0145020. PubMed ID: 26684001 [TBL] [Abstract][Full Text] [Related]
4. 18F-FDG uptake as a biologic prognostic factor for recurrence in patients with surgically resected non-small cell lung cancer. Higashi K; Ueda Y; Arisaka Y; Sakuma T; Nambu Y; Oguchi M; Seki H; Taki S; Tonami H; Yamamoto I J Nucl Med; 2002 Jan; 43(1):39-45. PubMed ID: 11801701 [TBL] [Abstract][Full Text] [Related]
5. Prognostic value of whole-body total lesion glycolysis at pretreatment FDG PET/CT in non-small cell lung cancer. Chen HH; Chiu NT; Su WC; Guo HR; Lee BF Radiology; 2012 Aug; 264(2):559-66. PubMed ID: 22692034 [TBL] [Abstract][Full Text] [Related]
6. Prognostic value of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with Barcelona Clinic Liver Cancer stages 0 and A hepatocellular carcinomas: a multicenter retrospective cohort study. Hyun SH; Eo JS; Lee JW; Choi JY; Lee KH; Na SJ; Hong IK; Oh JK; Chung YA; Song BI; Kim TS; Kim KS; Moon DH; Yun M Eur J Nucl Med Mol Imaging; 2016 Aug; 43(9):1638-45. PubMed ID: 26936852 [TBL] [Abstract][Full Text] [Related]
7. Risk stratification in patients with advanced-stage breast cancer by pretreatment [(18) F]FDG PET/CT. Chen S; Ibrahim NK; Yan Y; Wong ST; Wang H; Wong FC Cancer; 2015 Nov; 121(22):3965-74. PubMed ID: 26249241 [TBL] [Abstract][Full Text] [Related]
8. Prognostic value of preoperative intratumoral FDG uptake heterogeneity in early stage uterine cervical cancer. Chung HH; Kang SY; Ha S; Kim JW; Park NH; Song YS; Cheon GJ J Gynecol Oncol; 2016 Mar; 27(2):e15. PubMed ID: 26768781 [TBL] [Abstract][Full Text] [Related]
9. Comparison of standardized uptake value of 18F-FDG-PET-CT with 21-gene recurrence score in estrogen receptor-positive, HER2-negative breast cancer. Ahn SG; Lee JH; Lee HW; Jeon TJ; Ryu YH; Kim KM; Sohn J; Yun M; Lee SA; Jeong J; Kim SI PLoS One; 2017; 12(4):e0175048. PubMed ID: 28419166 [TBL] [Abstract][Full Text] [Related]
10. Use of (18)F-FDG PET to predict tumor progression and survival in patients with intermediate hepatocellular carcinoma treated by transarterial chemoembolization. Kim MJ; Kim YS; Cho YH; Jang HY; Song JY; Lee SH; Jeong SW; Kim SG; Jang JY; Kim HS; Kim BS; Lee WH; Park JM; Lee JM; Lee MH; Choi DL Korean J Intern Med; 2015 May; 30(3):308-15. PubMed ID: 25995661 [TBL] [Abstract][Full Text] [Related]
11. 18F-FDG PET/CT is a prognostic biomarker in patients affected by bone metastases from breast cancer in comparison with 18F-NaF PET/CT. Piccardo A; Puntoni M; Morbelli S; Massollo M; Bongioanni F; Paparo F; Altrinetti V; Gonella R; Gennari A; Iacozzi M; Sambuceti G; DeCensi A Nuklearmedizin; 2015; 54(4):163-72. PubMed ID: 26165806 [TBL] [Abstract][Full Text] [Related]
12. Preoperative 18F-FDG PET/CT predicts disease-free survival in patients with primary invasive ductal breast cancer. Jo JE; Kim JY; Lee SH; Kim S; Kang T Acta Radiol; 2015 Dec; 56(12):1463-70. PubMed ID: 25406431 [TBL] [Abstract][Full Text] [Related]
13. Stratifying triple-negative breast cancer prognosis using 18F-FDG-PET/CT imaging. Yue Y; Cui X; Bose S; Audeh W; Zhang X; Fraass B Breast Cancer Res Treat; 2015 Oct; 153(3):607-16. PubMed ID: 26346756 [TBL] [Abstract][Full Text] [Related]
14. Pelvic lymph node F-18 fluorodeoxyglucose uptake as a prognostic biomarker in newly diagnosed patients with locally advanced cervical cancer. Kidd EA; Siegel BA; Dehdashti F; Grigsby PW Cancer; 2010 Mar; 116(6):1469-75. PubMed ID: 20108309 [TBL] [Abstract][Full Text] [Related]
15. Standardized uptake value on positron emission tomography/computed tomography predicts prognosis in patients with locally advanced pancreatic cancer. Wang SL; Cao S; Sun YN; Wu R; Chi F; Tang MY; Jin XY; Chen XD Abdom Imaging; 2015 Oct; 40(8):3117-21. PubMed ID: 26350284 [TBL] [Abstract][Full Text] [Related]
16. Limited prognostic value of dual time point F-18 FDG PET/CT in patients with early stage (stage I & II) non-small cell lung cancer (NSCLC). Kim SJ; Kim YK; Kim IJ; Kim YD; Lee MK Radiother Oncol; 2011 Jan; 98(1):105-8. PubMed ID: 21159395 [TBL] [Abstract][Full Text] [Related]
17. Primary tumor maximum standardized uptake value measured on 18F-fluorodeoxyglucose positron emission tomography-computed tomography is a prognostic value for survival in bile duct and gallbladder cancer. Lee JY; Kim HJ; Yim SH; Shin DS; Yu JH; Ju DY; Park JH; Park DI; Cho YK; Sohn CI; Jeon WK; Kim BI Korean J Gastroenterol; 2013 Oct; 62(4):227-33. PubMed ID: 24162710 [TBL] [Abstract][Full Text] [Related]
18. Residual ¹⁸F-FDG-PET uptake 12 weeks after stereotactic ablative radiotherapy for stage I non-small-cell lung cancer predicts local control. Bollineni VR; Widder J; Pruim J; Langendijk JA; Wiegman EM Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):e551-5. PubMed ID: 22417800 [TBL] [Abstract][Full Text] [Related]
19. 18F-FDG PET in patients with esophageal squamous cell carcinoma undergoing curative surgery: prognostic implications. Choi JY; Jang HJ; Shim YM; Kim K; Lee KS; Lee KH; Choi Y; Choe YS; Kim BT J Nucl Med; 2004 Nov; 45(11):1843-50. PubMed ID: 15534053 [TBL] [Abstract][Full Text] [Related]
20. Prognostic Value of Pretherapeutic Tumor-to-Blood Standardized Uptake Ratio in Patients with Esophageal Carcinoma. Bütof R; Hofheinz F; Zöphel K; Stadelmann T; Schmollack J; Jentsch C; Löck S; Kotzerke J; Baumann M; van den Hoff J J Nucl Med; 2015 Aug; 56(8):1150-6. PubMed ID: 26089549 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]